

AIDS VACCINE ADVOCACY COALITION

**FINANCIAL STATEMENTS
AND
SUPPLEMENTARY INFORMATION**

DECEMBER 31, 2015 AND 2014

AIDS VACCINE ADVOCACY COALITION

TABLE OF CONTENTS

	Page
Independent Auditors' Report	1-2
Financial Statements	
Statements of Financial Position	3
Statements of Activities	4
Statements of Cash Flows	5
Notes to Financial Statements	6-10
Supplementary Information	
Independent Auditors' Report on Supplementary Information	12
Schedule of Functional Expenses	13



LOTZ AND CARR
CERTIFIED PUBLIC ACCOUNTANTS, LLP
300 EAST 42ND ST., NEW YORK, NY 10017
212-697-2299 Fax 212-949-1768

INDEPENDENT AUDITORS' REPORT

To the Board of Directors of
AIDS Vaccine Advocacy Coalition

We have audited the accompanying financial statements of AIDS Vaccine Advocacy Coalition (a nonprofit organization), which comprise the statements of financial position as of December 31, 2015 and 2014, and the related statements of activities and cash flows for the years then ended, and the related notes to the financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of AIDS Vaccine Advocacy Coalition as of December 31, 2015 and 2014, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of Am

Lotz + Carr, LLP

New York, New York
May 26, 2016

AIDS VACCINE ADVOCACY COALITION
STATEMENTS OF FINANCIAL POSITION
DECEMBER 31, 2015 AND 2014

	<u>2015</u>	<u>2014</u>
Assets		
Cash and cash equivalents (Notes 1b and 5)	\$1,041,360	\$1,930,382
Unconditional promises to give (Notes 1c and 2)	3,281,774	2,175,936
Prepaid expenses and other assets	89,596	130,710
Security deposits	65,407	65,407
Property and equipment, at cost, net of accumulated depreciation (Notes 1d and 3)	<u>138,951</u>	<u>173,270</u>
Total Assets	<u><u>\$4,617,088</u></u>	<u><u>\$4,475,705</u></u>
Liabilities and Net Assets		
Liabilities		
Accounts payable and accrued expenses	\$ 228,704	\$ 241,763
Grants payable (Note 1e)	312,079	342,778
Deferred revenue	-	41,773
Deferred rent (Note 1f)	<u>47,500</u>	<u>37,500</u>
Total Liabilities	<u>588,283</u>	<u>663,814</u>
Commitment and Contingency (Notes 7 and 8)		
Net Assets		
Unrestricted	859,214	842,057
Temporarily restricted (Note 4)	<u>3,169,591</u>	<u>2,969,834</u>
Total Net Assets	<u>4,028,805</u>	<u>3,811,891</u>
Total Liabilities and Net Assets	<u><u>\$4,617,088</u></u>	<u><u>\$4,475,705</u></u>

See notes to financial statements.

AIDS VACCINE ADVOCACY COALITION

STATEMENTS OF ACTIVITIES

YEARS ENDED DECEMBER 31, 2015 AND 2014

	2015			2014		
	Unrestricted	Temporarily Restricted	Total	Unrestricted	Temporarily Restricted	Total
Changes in Net Assets						
Revenues and Other Support						
Contributions (Note 1a)	\$ 24,255	\$ 5,392,673	\$5,416,928	\$ 22,220	\$ 5,540,813	\$5,563,033
Program services income	55,673	-	55,673	143,736	-	143,736
Interest income	2,732	-	2,732	5,200	-	5,200
Donated services and materials (Note 6)	43,890	-	43,890	18,035	-	18,035
Other income	6	-	6	31	-	31
	<u>126,556</u>	<u>5,392,673</u>	<u>5,519,229</u>	<u>189,222</u>	<u>5,540,813</u>	<u>5,730,035</u>
Net assets released from restrictions	<u>5,192,916</u>	<u>(5,192,916)</u>	<u>-</u>	<u>4,996,032</u>	<u>(4,996,032)</u>	<u>-</u>
Total Revenues and Other Support	<u>5,319,472</u>	<u>199,757</u>	<u>5,519,229</u>	<u>5,185,254</u>	<u>544,781</u>	<u>5,730,035</u>
Expenses						
Program Services	<u>4,609,664</u>	<u>-</u>	<u>4,609,664</u>	<u>4,581,815</u>	<u>-</u>	<u>4,581,815</u>
Supporting Services						
Management and general	569,720	-	569,720	540,106	-	540,106
Fundraising	122,931	-	122,931	57,812	-	57,812
Total Supporting Services	<u>692,651</u>	<u>-</u>	<u>692,651</u>	<u>597,918</u>	<u>-</u>	<u>597,918</u>
Total Expenses	<u>5,302,315</u>	<u>-</u>	<u>5,302,315</u>	<u>5,179,733</u>	<u>-</u>	<u>5,179,733</u>
Increase in net assets	17,157	199,757	216,914	5,521	544,781	550,302
Net assets, beginning of year	<u>842,057</u>	<u>2,969,834</u>	<u>3,811,891</u>	<u>836,536</u>	<u>2,425,053</u>	<u>3,261,589</u>
Net Assets, End of Year	<u>\$ 859,214</u>	<u>\$ 3,169,591</u>	<u>\$4,028,805</u>	<u>\$ 842,057</u>	<u>\$ 2,969,834</u>	<u>\$3,811,891</u>

See notes to financial statements.

AIDS VACCINE ADVOCACY COALITION

STATEMENTS OF CASH FLOWS

YEARS ENDED DECEMBER 31, 2015 AND 2014

	<u>2015</u>	<u>2014</u>
Cash Flows From Operating Activities		
Increase in net assets	\$ 216,914	\$ 550,302
Adjustments to reconcile increase in net assets to net cash provided (used) by operating activities:		
Depreciation and amortization	76,627	65,284
(Increase) decrease in:		
Unconditional promises to give	(1,105,838)	349,849
Prepaid expenses and other assets	41,114	(35,758)
Increase (decrease) in:		
Accounts payable and accrued expenses	(13,059)	(47,977)
Grants payable	(30,699)	118,695
Deferred revenue	(41,773)	41,773
Deferred rent	10,000	10,000
Net Cash Provided (Used) By Operating Activities	<u>(846,714)</u>	<u>1,052,168</u>
Cash Flows From Investing Activities		
Acquisition of property and equipment	<u>(42,308)</u>	<u>(105,945)</u>
Net increase (decrease) in cash and cash equivalents	(889,022)	946,223
Cash and cash equivalents, beginning of year	<u>1,930,382</u>	<u>984,159</u>
Cash and Cash Equivalents, End of Year	<u><u>\$1,041,360</u></u>	<u><u>\$1,930,382</u></u>

See notes to financial statements.

AIDS VACCINE ADVOCACY COALITION**NOTES TO FINANCIAL STATEMENTS****DECEMBER 31, 2015 AND 2014****Note 1 - Organization and Summary of Significant Accounting Policies****a - Organization**

AIDS Vaccine Advocacy Coalition ("AVAC") is an international non-profit organization that uses public education, policy analysis, advocacy and community mobilization to accelerate the ethical development and global delivery of AIDS vaccines and other prevention technologies and interventions. The purposes of AVAC are to:

- increase public awareness of and community participation in the efforts to advance the need for a well-funded, coordinated HIV prevention research program;
- identify and mitigate or eliminate barriers to the development of and access to new HIV vaccines and other prevention options; and
- promote increased resources for HIV vaccine and prevention research by government agencies, private industry, academia and non-governmental organizations

For the years ended December 31, 2015 and 2014, approximately 98% and 97%, respectively, of total contributions were from one foundation and one government agency.

b - Cash and Cash Equivalents

For purposes of the statement of cash flows, AVAC considers all highly liquid debt instruments, including money market funds, purchased with a maturity of three months or less, to be cash equivalents.

c - Contributions and Unconditional Promises to Give

Contributions are recognized when the donor makes a promise to give to AVAC, that is, in substance, unconditional. Contributions that are restricted by the donor are reported as increases in temporarily or permanently restricted net assets, depending on the nature of the restriction. When a restriction expires (that is, when stipulated time restriction ends or purpose restriction is accomplished), temporarily restricted net assets are reclassified to unrestricted net assets and reported in the statement of activities as net assets released from restrictions.

AIDS VACCINE ADVOCACY COALITION**NOTES TO FINANCIAL STATEMENTS****DECEMBER 31, 2015 AND 2014****Note 1 - Organization and Summary of Significant Accounting Policies (continued)****d - Property and Equipment**

Purchased property and equipment are carried at cost. Donated property and equipment are carried at the approximate fair value at the date of donation. Property and equipment are depreciated using the straight-line method over the estimated useful life of the related asset.

e - Grants

Grants are accrued at the time authorized. At December 31, 2015 and 2014, grants payable are due to be paid within one year.

f - Rent Expense

AVAC records rent expense associated with its office lease on the straight-line basis over the life of the lease (Note 8a). The difference between the straight-line amount and the amount actually paid in accordance with the terms of the lease is recorded as a liability and an expense in the accompanying financial statements.

g - Financial Statement Presentation

AVAC reports information regarding their financial position and activities according to three classes of net assets: unrestricted net assets, temporarily restricted net assets and permanently restricted net assets.

h - Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Actual results could differ from those estimates.

i - Tax Status

AIDS Vaccine Advocacy Coalition is a not-for-profit corporation exempt from federal income taxes under Section 501(c)(3) of the Internal Revenue Code and has been designated as an organization which is not a private foundation.

j - Subsequent Events

AVAC has evaluated subsequent events through May 26, 2016, the date that the financial statements are considered available to be issued.

AIDS VACCINE ADVOCACY COALITION

NOTES TO FINANCIAL STATEMENTS

DECEMBER 31, 2015 AND 2014

Note 2 - Promises to Givea - Unconditional Promises to Give

Unconditional promises to give at December 31 were due as follows:

	2015		
	<u>Unrestricted</u>	<u>Temporarily Restricted</u>	<u>Total</u>
Due in less than one year	\$300,795	\$1,398,016	\$1,698,811
Due in one to three years	-	1,759,963	1,759,963
	<u>300,795</u>	<u>3,157,979</u>	<u>3,458,774</u>
Less: Discount to present value	-	(177,000)	(177,000)
Total	<u>\$300,795</u>	<u>\$2,980,979</u>	<u>\$3,281,774</u>
	2014		
	<u>Unrestricted</u>	<u>Temporarily Restricted</u>	<u>Total</u>
Due in less than one year	\$316,922	\$1,542,515	\$1,859,437
Due in one to three years	-	335,799	335,799
	<u>316,922</u>	<u>1,878,314</u>	<u>2,195,236</u>
Less: Discount to present value	-	(19,300)	(19,300)
Total	<u>\$316,922</u>	<u>\$1,859,014</u>	<u>\$2,175,936</u>

Unconditional promises to give due after one year are discounted to net present value using a discount rate of 3%. Uncollectible promises to give are expected to be insignificant.

b - Conditional Promises to Give

During 2014, AVAC received a commitment of funding of approximately \$15 million from the Bill and Melinda Gates Foundation to be paid over a four year period. The funding is conditional upon AVAC maintaining a specific level of public support percentage as defined in connection with Schedule A of IRS Form 990.

As of December 31, 2015, AVAC has received \$7,481,445 of the total committed funding. The balance of the funding will be recorded within the financial statements as AVAC annually meets the condition of the grant and receives the subsequent payments.

AIDS VACCINE ADVOCACY COALITION

NOTES TO FINANCIAL STATEMENTS

DECEMBER 31, 2015 AND 2014

Note 3 - Property and Equipment

Property and equipment consist of the following at December 31:

	<u>Life</u>	<u>2015</u>	<u>2014</u>
Computer equipment	3 years	\$157,887	\$164,166
Leasehold improvements	Life of lease	31,159	31,159
Furniture, fixtures and equipment	3-7 years	6,037	6,037
Website development costs	3 years	<u>264,983</u>	<u>235,733</u>
		460,066	437,095
Less: Accumulated depreciation		<u>(321,115)</u>	<u>(263,825)</u>
		<u>\$138,951</u>	<u>\$173,270</u>

Depreciation and amortization expense for the years ended December 31, 2015 and 2014 was \$76,627 and \$65,284, respectively.

Note 4 - Temporarily Restricted Net Assets

Temporarily restricted net assets are restricted for future periods and programs.

Note 5 - Concentration of Credit Risk

AVAC maintains cash balances at financial institutions located in New York. The cash balances, at times, exceeded federally insured limits.

Note 6 - Donated Services and Materials

Donated services and materials consist of the following:

	<u>2015</u>	<u>2014</u>
Travel expenses	\$38,010	\$13,041
Software and equipment	<u>5,880</u>	<u>4,994</u>
Total	<u>\$43,890</u>	<u>\$18,035</u>

AIDS VACCINE ADVOCACY COALITION

NOTES TO FINANCIAL STATEMENTS

DECEMBER 31, 2015 AND 2014

Note 7 - Pension Plan

AVAC has a 401k safe harbor retirement plan. The plan allows employee contributions pursuant to salary reduction agreements. In 2015 and 2014, AVAC made a 100% match on the first 3% of compensation deferred plus 50% match on the next 2% of compensation deferred. Pension expense for the years ended December 31, 2015 and 2014 was \$70,388 and \$60,961, respectively.

Note 8 - Commitment and Contingency

a - AVAC occupies office space under a lease which expires March 31, 2021 and provides minimum rental payments as follows:

<u>Year Ending December 31,</u>	
2016	\$153,817
2017	158,817
2018	158,817
2019	158,817
2020	158,817
Thereafter, through March 31, 2021	39,704

Rent expense for the years ended December 31, 2015 and 2014 was \$148,925 and \$149,222, respectively.

b - In September 2015, AVAC secured a \$300,000 line of credit with Amalgamated Bank. There were no borrowings against the line during the year ended December 31, 2015.

c - Government supported projects are subject to audit by the granting agency.

Note 9 - Functional Allocation of Expenses

The cost of providing the various program and supporting services has been summarized on a functional basis in the statement of activities. Accordingly, certain costs have been allocated by management among the programs and the supporting services benefited.

SUPPLEMENTARY INFORMATION



LUZ AND CARR
CERTIFIED PUBLIC ACCOUNTANTS, LLP
300 EAST 42ND ST., NEW YORK, NY 10017
212-697-2299 Fax 212-949-1768

**INDEPENDENT AUDITORS' REPORT
ON SUPPLEMENTARY INFORMATION**

To the Board of Directors of
AIDS Vaccine Advocacy Coalition

We have audited the financial statements of AIDS Vaccine Advocacy Coalition as of and for the years ended December 31, 2015 and 2014, and our report thereon dated May 26, 2016, which expressed an unmodified opinion on those financial statements, appears on pages 1 and 2. Our audits were conducted for the purpose of forming an opinion on the financial statements as a whole. The Schedule of Functional Expenses for the year ended December 31, 2015 with comparative totals for 2014 is presented for purposes of additional analysis and is not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audits of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the information is fairly stated in all material respects in relation to the financial statements as a whole.

Lutz + Carr, LLP

New York, New York
May 26, 2016

AIDS VACCINE ADVOCACY COALITION

SCHEDULE OF FUNCTIONAL EXPENSES

YEAR ENDED DECEMBER 31, 2015 WITH COMPARATIVE TOTALS FOR 2014

	Program Services	Supporting Services			2015	2014
		Management and General	Fundraising	Total	Total Expenses	Total Expenses
Salaries	\$1,594,169	\$ 367,516	\$ 43,567	\$411,083	\$2,005,252	\$1,885,903
Employee benefits	372,432	79,782	8,042	87,824	460,256	426,680
Payroll taxes	99,892	31,000	3,090	34,090	133,982	129,686
Contract labor	645,566	4,025	40,995	45,020	690,586	541,412
Reports and publications	140,537	914	357	1,271	141,808	167,573
Meetings and travel	427,791	5,065	5,598	10,663	438,454	412,571
Conferences	49,805	-	-	-	49,805	56,029
AVAC meetings	301,615	5,281	1,466	6,747	308,362	203,924
Grants and fellowships	510,992	-	-	-	510,992	760,764
Insurance	7,527	2,336	589	2,925	10,452	8,844
Professional fees	76,845	22,220	4,992	27,212	104,057	107,905
Postage and delivery	9,010	-	1,888	1,888	10,898	20,630
Office expense and supplies	62,901	11,222	2,999	14,221	77,122	82,908
Telephone	71,726	13,832	1,946	15,778	87,504	103,450
Occupancy	149,358	15,101	5,116	20,217	169,575	173,222
Depreciation and amortization	66,617	8,233	1,777	10,010	76,627	65,284
Public relations expense	10,885	-	-	-	10,885	11,070
Processing fees	11,996	3,193	509	3,702	15,698	21,878
Total Expenses, 2015	<u>\$4,609,664</u>	<u>\$ 569,720</u>	<u>\$ 122,931</u>	<u>\$692,651</u>	<u>\$5,302,315</u>	
Total Expenses, 2014	<u>\$4,581,815</u>	<u>\$ 540,106</u>	<u>\$ 57,812</u>	<u>\$597,918</u>		<u>\$5,179,733</u>

See independent auditors' report on supplementary information.